14,696 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Acquired by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC purchased a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,696 shares of the specialty pharmaceutical company's stock, valued at approximately $439,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of COLL. Invesco Ltd. increased its position in shares of Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after purchasing an additional 289,335 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Collegium Pharmaceutical by 0.3% during the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock worth $47,603,000 after purchasing an additional 5,480 shares in the last quarter. Northern Trust Corp increased its position in shares of Collegium Pharmaceutical by 5.6% during the fourth quarter. Northern Trust Corp now owns 385,157 shares of the specialty pharmaceutical company's stock worth $11,035,000 after purchasing an additional 20,490 shares in the last quarter. Royce & Associates LP increased its position in shares of Collegium Pharmaceutical by 11.0% during the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock worth $9,728,000 after purchasing an additional 33,674 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Collegium Pharmaceutical by 319.4% during the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock worth $8,341,000 after purchasing an additional 221,903 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on COLL shares. Piper Sandler reiterated a "neutral" rating and set a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Needham & Company LLC reissued a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Wall Street Zen lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday. Finally, HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Monday, March 24th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $43.75.

Collegium Pharmaceutical Stock Performance

COLL traded up $0.55 during trading on Monday, reaching $30.90. The company's stock had a trading volume of 431,620 shares, compared to its average volume of 399,434. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $42.29. The company's fifty day moving average price is $29.22 and its 200-day moving average price is $29.50. The company has a market capitalization of $992.82 million, a price-to-earnings ratio of 25.33 and a beta of 0.64. The company has a debt-to-equity ratio of 3.30, a quick ratio of 1.01 and a current ratio of 1.08.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The business had revenue of $177.76 million during the quarter, compared to analysts' expectations of $174.96 million. During the same period in the prior year, the firm posted $1.45 EPS. Collegium Pharmaceutical's revenue for the quarter was up 22.7% compared to the same quarter last year. On average, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director John Gordon Freund sold 6,601 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $30.62, for a total transaction of $202,122.62. Following the sale, the director owned 70,658 shares of the company's stock, valued at $2,163,547.96. The trade was a 8.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.